Every material Form 8-K Waters filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Waters reported third-quarter 2024 sales of $740 million, up 4% from a year earlier, and GAAP diluted EPS of $2.71, up from $2.27. The company said sales and EPS exceeded its guidance and raised its full-year 2024 sales and non-GAAP EPS guidance, which matters to shareholders because it signals stronger expected results for the year.
Q3 2024 sales were $740 million, up 4% as reported from $712 million in Q3 2023.
GAAP diluted EPS was $2.71 vs. $2.27 a year earlier; non-GAAP EPS was $2.93 vs. $2.84.
Full-year 2024 non-GAAP EPS guidance raised to $11.67 to $11.87.
Fourth-quarter 2024 non-GAAP EPS is expected at $3.90 to $4.10.
Waters Corporation increased its board from 9 to 10 members and appointed Heather Knight, Executive Vice President and Group President of Medical Products and Therapies at Baxter International, effective August 14, 2024. Her compensation includes an initial equity grant valued at $91,666 and a prorated cash retainer of $54,130 through the 2025 annual meeting, which shareholders will see in the company's disclosures.
Board expanded from 9 to 10 members on August 13, 2024; Knight's appointment is effective August 14, 2024.
Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International.
Initial equity grant valued at $91,666, split 50% restricted stock and 50% non-qualified stock options, vesting on the first anniversary of grant.
Prorated cash retainer of $54,130 for service until the 2025 annual meeting; the Board determined she is independent under NYSE standards.
Waters reported second quarter 2024 sales of $709 million, down 4% as reported from $741 million a year earlier, with the company saying results exceeded its own reported guidance. Non-GAAP EPS was $2.63 versus $2.80 a year earlier, and GAAP diluted EPS was $2.40 versus $2.55, while the company now expects full-year 2024 non-GAAP EPS of $11.55 to $11.65.
Q2 2024 sales were $709 million, down 4% as reported and 4% in organic constant currency; currency reduced sales 2% and acquisitions added 2%.
Instrument system sales fell 14% as reported, while recurring revenues rose 4%; Academic & Government sales fell 15%.
Full-year 2024 organic constant currency sales growth is now expected at -2.0% to -0.5%, with non-GAAP EPS of $11.55 to $11.65.
Third quarter 2024 non-GAAP EPS is expected at $2.60 to $2.70, and the company cited the potential for a more gradual market improvement in the second half.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Waters filing is on SEC EDGAR ↗. 8-K briefs of other companies →